Who is sponsoring DINAMIC?

DINAMIC is sponsored by EpicentRx, Inc..

What condition does DINAMIC study?

DINAMIC studies Malignant Solid Tumor, Lymphomas.

What drugs are being tested in DINAMIC?

Interventions: RRx-001, RRx-001, RRx-001, RRx-001, RRx-001, RRx-001.

What is the status of DINAMIC?

DINAMIC is currently COMPLETED.

Last reviewed 2024-08-19 · How we verify

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies (DINAMIC)

NCT01359982 Phase 1 COMPLETED Results posted

The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.

Details

Lead sponsor	EpicentRx, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	26
Start date	2011-09
Completion	2015-02

Conditions

Malignant Solid Tumor
Lymphomas

Interventions

RRx-001
RRx-001
RRx-001
RRx-001
RRx-001
RRx-001

Primary outcomes

Number of Patients Who Had an Adverse Events — From time of receiving a dose of RRx-001 through 92 days
The total number of patients who experienced at least one adverse event while receiving treatment.

Countries

United States